

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2024 February 28; 30(8): 779-993



**EDITORIAL**

- 779 Immunotherapy of gastric cancer: Present status and future perspectives  
*Triantafyllidis JK, Konstadoulakis MM, Papalois AE*
- 794 Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment  
*Christodoulidis G, Kouliou MN, Koumarelas KE*
- 799 Management of autoimmune hepatitis induced by hepatitis delta virus  
*Gigi E, Lagopoulos V, Liakos A*
- 806 Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era  
*Zhong JH*

**OPINION REVIEW**

- 811 Nonsteroidal anti-inflammatory drugs before endoscopic ultrasound guided tissue acquisition to reduce the incidence of post procedural pancreatitis  
*de Jong M, van Delft F, Roozen C, van Geenen EJ, Bisseling T, Siersema P, Bruno M*

**REVIEW**

- 817 Autoimmune pancreatitis: Cornerstones and future perspectives  
*Gallo C, Dispinzieri G, Zucchini N, Invernizzi P, Massironi S*

**MINIREVIEWS**

- 833 Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect  
*Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, Li Z*

**ORIGINAL ARTICLE****Retrospective Study**

- 843 Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus  
*Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL*
- 855 Immunoglobulin G-mediated food intolerance and metabolic syndrome influence the occurrence of reflux esophagitis in *Helicobacter pylori*-infected patients  
*Wang LH, Su BB, Wang SS, Sun GC, Lv KM, Li Y, Shi H, Chen QQ*
- 863 Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor  
*Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ*

**Observational Study**

- 881 Mitochondrial dysfunction affects hepatic immune and metabolic remodeling in patients with hepatitis B virus-related acute-on-chronic liver failure  
*Zhang Y, Tian XL, Li JQ, Wu DS, Li Q, Chen B*

**Basic Study**

- 901 Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma  
*Wang YY, Shen MM, Gao J*
- 919 Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma  
*Wang RY, Yang JL, Xu N, Xu J, Yang SH, Liang DM, Li JZ, Zhu H*

**SYSTEMATIC REVIEWS**

- 943 Quality of life after pancreatic surgery  
*Li SZ, Zhen TT, Wu Y, Wang M, Qin TT, Zhang H, Qin RY*

**META-ANALYSIS**

- 956 Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis  
*Jiang MJ, Wu MC, Duan ZH, Wu J, Xu XT, Li J, Meng QH*

**SCIENTOMETRICS**

- 969 Bibliometrics analysis based on the Web of Science: Current trends and perspective of gastric organoid during 2010-2023  
*Jiang KL, Jia YB, Liu XJ, Jia QL, Guo LK, Wang XX, Yang KM, Wu CH, Liang BB, Ling JH*

**CASE REPORT**

- 984 Cronkhite-Canada syndrome with esophagus involvement and six-year follow-up: A case report  
*Tang YC*

**LETTER TO THE EDITOR**

- 991 Monitoring of hepatocellular carcinoma  
*Akkari I, Jaziri H*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Neal Shahidi, MD, FRCPC, PhD, Assistant Professor, Department of Medicine, Division of Gastroenterology, St Paul's Hospital, Vancouver V6Z 2K5, British Columbia, Canada. nshahidi@providencehealth.bc.ca

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJG* as 4.3; Quartile category: Q2. The *WJG*'s CiteScore for 2021 is 8.3.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

February 28, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University  
Biliary Tract Disease Institute, Fudan University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/gerinfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/gerinfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/gerinfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

<https://www.shca.org.cn>  
<https://www.zs-hospital.sh.cn>

## Retrospective Study

**Immunoglobulin G-mediated food intolerance and metabolic syndrome influence the occurrence of reflux esophagitis in *Helicobacter pylori*-infected patients**

Li-Hui Wang, Bin-Bin Su, Sheng-Shu Wang, Guan-Chao Sun, Kun-Ming Lv, Yi Li, Hui Shi, Qian-Qian Chen

**Specialty type:** Gastroenterology and hepatology**Provenance and peer review:** Unsolicited article; Externally peer reviewed.**Peer-review model:** Single blind**Peer-review report's scientific quality classification**Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0**P-Reviewer:** Ushiku T, Japan**Received:** December 8, 2023**Peer-review started:** December 8, 2023**First decision:** December 27, 2023**Revised:** January 4, 2024**Accepted:** January 29, 2024**Article in press:** January 29, 2024**Published online:** February 28, 2024**Li-Hui Wang, Guan-Chao Sun, Kun-Ming Lv**, Medical College, Chinese PLA General Hospital, Beijing 100853, China**Li-Hui Wang, Bin-Bin Su, Guan-Chao Sun, Kun-Ming Lv, Hui Shi**, Department of Gastroenterology, Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China**Sheng-Shu Wang**, Institute of Geriatrics, The 2<sup>nd</sup> Medical Center, Beijing Key Laboratory of Aging and Geriatrics, National Clinical Research Center for Geriatrics Diseases, Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China**Yi Li, Qian-Qian Chen**, Department of Gastroenterology, First Medical Center of Chinese PLA General Hospital, Beijing 100853, China**Corresponding author:** Qian-Qian Chen, MD, Associate Chief Physician, Associate Professor, Department of Gastroenterology, First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. [qian\\_qian\\_chen@163.com](mailto:qian_qian_chen@163.com)**Abstract****BACKGROUND**

Reflux esophagitis has an increasing prevalence and complex and diverse symptoms. Identifying its risk factors is crucial to understanding the etiology, prevention, and management of the disease. The occurrence of reflux esophagitis may be associated with food reactions, *Helicobacter pylori* (*H. pylori*) infection, and metabolic syndromes.

**AIM**

To investigate the risk factors for reflux esophagitis and analyze the effects of immunoglobulin (Ig) G-mediated food intolerance, *H. pylori* infection, and metabolic syndrome on reflux esophagitis.

**METHODS**

Outpatients attending the Second Medical Center of the PLA General Hospital between 2017 and 2021 were retrospectively enrolled. The patients' basic information, test results, gastroscopy results, *H. pylori* test results, and IgG-mediated food intolerance results were collected. Multivariate logistic regression analysis was used to analyze risk factors for reflux esophagitis. Statistical

mediation analysis was used to evaluate the effects of IgG-mediated food intolerance and metabolic syndrome on *H. pylori* infection affecting reflux esophagitis.

## RESULTS

A total of 7954 outpatients were included; the prevalence of reflux esophagitis, IgG-mediated food intolerance, *H. pylori* infection, and metabolic syndrome were 20.84%, 61.77%, 35.91%, and 60.15%, respectively. Multivariate analysis showed that the independent risk factors for reflux esophagitis included IgG-mediated food intolerance (OR = 1.688, 95%CI: 1.497-1.903,  $P < 0.00001$ ) and metabolic syndrome (OR = 1.165, 95%CI: 1.030-1.317,  $P = 0.01484$ ), and the independent protective factor for reflux esophagitis was *H. pylori* infection (OR = 0.400, 95%CI: 0.351-0.456,  $P < 0.00001$ ). IgG-mediated food intolerance had a partially positive mediating effect on *H. pylori* infection as it was associated with reduced occurrence of reflux esophagitis ( $P = 0.0200$ ). Metabolic syndrome had a partially negative mediating effect on *H. pylori* infection and reduced the occurrence of reflux esophagitis ( $P = 0.0220$ ).

## CONCLUSION

Patients with IgG-mediated food intolerance and metabolic syndrome were at higher risk of developing reflux esophagitis, while patients with *H. pylori* infection were at lower risk. IgG-mediated food intolerance reduced the risk of reflux esophagitis pathogenesis in patients with *H. pylori* infection; however, metabolic syndrome increased the risk of patients with *H. pylori* infection developing reflux esophagitis.

**Key Words:** Gastroesophageal reflux; Esophagitis; Food intolerance; Metabolic syndrome; *Helicobacter pylori*; Chemokines

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** This retrospective study investigated the effects of IgG-mediated food intolerance, *Helicobacter pylori* (*H. pylori*) infection, and metabolic syndrome on reflux esophagitis. In 7954 outpatients, the prevalence of reflux esophagitis was 20.84%. Patients with IgG-mediated food intolerance and metabolic syndrome are at higher risk of developing reflux esophagitis, while patients with *H. pylori* infection are at lower risk. IgG-mediated food intolerance reduces the risk of reflux esophagitis pathogenesis in patients with *H. pylori* infection; however, metabolic syndrome increases the risk of patients with *H. pylori* infection developing reflux esophagitis.

**Citation:** Wang LH, Su BB, Wang SS, Sun GC, Lv KM, Li Y, Shi H, Chen QQ. Immunoglobulin G-mediated food intolerance and metabolic syndrome influence the occurrence of reflux esophagitis in *Helicobacter pylori*-infected patients. *World J Gastroenterol* 2024; 30(8): 855-862

**URL:** <https://www.wjgnet.com/1007-9327/full/v30/i8/855.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v30.i8.855>

## INTRODUCTION

Gastroesophageal reflux disease (GERD) is a range of diseases arising from the reflux of gastroduodenal content, and its pathogenesis is related to the immuno-inflammatory cascade[1]. Reflux esophagitis (RE), a phenotype of GERD, is defined as a visible mucosal rupture in the distal esophagus[2]. RE accounts for 30% of GERD cases, with an increasing prevalence and complex and diverse symptoms which greatly affect the quality of life; its long-term treatment requirements consume significant healthcare resources and create a socioeconomic burden[3]. Identifying the risk factors for RE is crucial to understanding the etiology, prevention, and management of the disease.

Food intolerance (FI) refers to the discomfort caused by a food or food component at a dose that is normally tolerated; this is responsible for most adverse food reactions. FI can be asymptomatic and manifest only as a high immunoglobulin (Ig) G response to stimulation by specific food antigens[4]. Certain foods can cause an imbalance between pro-inflammatory and anti-inflammatory cytokines, which is conducive to the production of an inflammatory environment and activation of the immune system[5]; this phenomenon may affect the development of RE. Metabolic syndrome is a risk factor for RE[6,7]. The effects of *Helicobacter pylori* (*H. pylori*) infection on reflux remain controversial[8-10]. This study aimed to explore the risk factors for RE and analyze the effects of IgG-mediated FI, *H. pylori* infection, and metabolic syndrome on RE.

## MATERIALS AND METHODS

### Research methods

This was a retrospective cross-sectional study. Outpatients attending the Second Medical Center of PLA General Hospital between 2017 and 2021 were enrolled.

The inclusion criteria were as follows: (1) Successful gastroscopy at our hospital; (2) successful completion of the IgG-mediated FI test; and (3) successful completion of the *H. pylori* test.

The exclusion criteria were as follows: (1) Missing test results; and (2) severe cardiovascular, cerebrovascular, or consciousness impairment preventing completion of the examination.

### Basic information

The data collected from outpatient records included the following: (1) Basic information: age, sex, systolic blood pressure, diastolic blood pressure, smoking history, and drinking history; (2) test results: white blood cell count, hemoglobin, C-reactive protein, folic acid, homocysteine, brain natriuretic peptide precursor, total cholesterol, fasting blood glucose, creatinine, total protein, and 25-hydroxyvitamin D3; (3) diseases: metabolic syndrome and *H. pylori* infection; (4) gastroscopy results: presence of RE; and (5) IgG-mediated FI results.

### Diagnostic criteria

**Diagnostic criteria for reflux esophagitis:** RE, diagnosed by the presence of mucosal rupture, was detected by gastroscopy and classified according to the current international common Los Angeles grading (LA) standard. LA-A type is categorized by the presence of one or more mucosal breakages  $\leq 5$  mm in length, LA-B type is categorized by the presence of one or more mucosal breakages  $> 5$  mm in length with no fusion lesion, LA-C type is categorized by the presence of mucosal breakages with fusion lesions  $< 75\%$  of the esophageal circumference, and LA-D type is categorized by the presence of mucosal breakages with fusion lesions  $\geq 75\%$  of the esophageal circumference[3].

**Diagnostic criteria for IgG-mediated FI:** ELISA was performed to detect delayed allergens, namely, specific IgG antibodies for 21 foods (beef, chicken, cod, corn, crab, egg, mushroom, milk, pork, rice, shrimp, soybean, tomatoes, wheat, brewer's yeast, garlic, ginger, onion, cottage cheese, red pepper, and sesame). All reagents were equilibrated to room temperature (20 °C-28 °C) and a standard curve was drawn. The absorbance value of each microwell was read with a microplate reader and the concentration of IgG antibodies was evaluated based on the absorbance of each well and the standard curve. IgG-positive food was defined as IgG antibody concentrations  $\geq 50$  U/mL. IgG-mediated FI was diagnosed when there was  $\geq 1$  IgG-positive food[11].

**Diagnostic criteria for metabolic syndrome:** Metabolic syndrome was diagnosed by the presence of at least three of the following: (1) Abdominal obesity (namely, central obesity): waist circumference  $\geq 90$  cm for men and  $\geq 85$  cm for women; (2) hyperglycemia: fasting blood glucose  $\geq 6.1$  mmol/L or blood glucose  $\geq 7.8$  mmol/L obtained 2 h after sugar loading or patients diagnosed with diabetes who were receiving treatment; (3) hypertension: blood pressure  $\geq 130/85$  mmHg (1 mmHg = 0.133 kPa) or patients diagnosed with hypertension who were receiving treatment; (4) fasting triacylglycerol  $\geq 1.70$  mmol/L; and (5) fasting high-density lipoprotein cholesterol  $< 1.04$  mmol/L[12].

**Diagnostic criteria for *H. pylori* infection:** The diagnostic criteria for *H. pylori* infection included the use of a  $^{13}\text{C}$ -urea breath test or the histologic examination of gastric biopsy specimens as diagnostic tools[13].

### Statistical analysis

Normally distributed continuous variables are presented as means  $\pm$  SD, and independent *t*-tests were used for between-group comparisons. Categorical variables are presented as numbers or percentages, and  $\chi^2$  tests were used for between-group comparisons. Multivariate logistic regression analysis was used to analyze risk factors for RE. Mediation effect analysis was used to evaluate the effects of IgG-mediated FI and metabolic syndrome on the occurrence of RE caused by *H. pylori* infection. In this study, SPSS (version 26.0; IBM Corp., Armonk, NY, United States) was applied to organize and statistically analyze the data; a *P*-value  $< 0.05$  was considered statistically significant.

## RESULTS

### Baseline characteristics

A total of 7954 outpatients were included; 1658 (20.84%) had RE. Notably, RE had a high prevalence among older patients, men, and patients with smoking and alcohol consumption histories. Furthermore, comparing the diseases and test results between the non-RE and RE groups, the RE group demonstrated higher positive IgG-mediated FI, metabolic syndrome, white blood cell count, hemoglobin, homocysteine, fasting blood glucose, and creatinine levels and a lower rate of *H. pylori* infection; all *P*-values were  $< 0.05$  (Table 1).

### Multivariate analysis of influencing factors in reflux esophagitis

Multivariate analysis showed that the risk factors for RE included IgG-mediated FI and metabolic syndrome and that *H. pylori* infection was a protective factor for RE (Figure 1).

### Mediation effect analysis of IgG-mediated FI on *H. pylori* infection affecting reflux esophagitis

The  $\chi^2$  test was used to analyze IgG-mediated FI and *H. pylori* infection. The incidence of IgG-mediated FI was significantly lower in the *H. pylori*-infected group (1700/2856, 59.52%) than in the *H. pylori*-non-infected group (3213/5098, 63.02%; *P* = 0.002). The exposure variable was *H. pylori* infection, the outcome variable was RE, and IgG-mediated FI was used as the mediating variable in the mediation effect analysis. The results showed that the total effect of *H. pylori*

**Table 1** Baseline characteristics

Characteristics	Non-reflux esophagitis (n = 6296)	Reflux esophagitis (n = 1658)	P value
Basic information			
Age (yr), mean ± SD	49.76 ± 8.00	50.81 ± 7.83	< 0.001
Sex (male) [n (%)]	4177 (66.34)	1504 (90.71)	< 0.001
Systolic blood pressure (mmHg), mean ± SD	123.40 ± 137.49	126.12 ± 16.78	0.421
Diastolic blood pressure (mmHg), mean ± SD	80.58 ± 11.57	82.63 ± 11.06	< 0.001
Drinking history [n (%)]			< 0.001
No	2567 (40.77)	387 (23.34)	
Yes	3592 (57.05)	1231 (74.25)	
Abstain	137 (2.17)	40 (2.41)	
Smoking history [n (%)]			< 0.001
No	4073 (64.69)	788 (47.53)	
Yes	1777 (28.22)	720 (43.43)	
Abstain	446 (7.08)	150 (9.05)	
Test results			
White blood cell count (10 <sup>9</sup> /L), mean ± SD	5.87 ± 1.44	6.21 ± 1.55	< 0.001
Hemoglobin (g/L), mean ± SD	143.31 ± 15.33	150.17 ± 12.61	< 0.001
C-reactive protein (mg/L), mean ± SD	0.16 ± 0.36	0.16 ± 0.31	0.999
Folic acid (ng/mL), mean ± SD	9.50 ± 4.39	8.58 ± 4.05	< 0.001
Homocysteine (μmol/L), mean ± SD	12.35 ± 9.38	13.46 ± 6.96	< 0.001
Brain natriuretic peptide precursor (pg/mL), mean ± SD	34.59 ± 41.53	30.29 ± 49.06	< 0.001
Total cholesterol (mmol/L), mean ± SD	4.76 ± 0.90	4.72 ± 0.95	0.103
Fasting blood glucose (mmol/L), mean ± SD	5.50 ± 1.17	5.68 ± 1.20	< 0.001
Creatinine (μmol/L), mean ± SD	67.92 ± 13.97	72.21 ± 12.79	< 0.001
Total protein (g/L), mean ± SD	70.14 ± 5.39	69.82 ± 5.25	0.031
25-hydroxyvitamin D3 (ng/mL), mean ± SD	19.79 ± 6.01	20.13 ± 6.14	0.040
Diseases [n (%)]			
IgG-mediated food intolerance	3781 (60.05)	1132 (68.28)	< 0.001
<i>Helicobacter pylori</i> infection	2478 (39.36)	378 (22.80)	< 0.001
Metabolic syndrome	3671 (58.31)	1113 (67.13)	< 0.001

Ig: Immunoglobulin.

infection on RE was -0.122064, the direct effect of *H. pylori* infection on RE was -0.119349, the mediation effect of *H. pylori* infection on RE through IgG-mediated FI was -0.002715, and the mediation effect accounted for 0.022242 of the total effect; the effects showed statistically significant differences (all *P* values < 0.05) (Table 2). IgG-mediated FI had a partially positive mediating effect on *H. pylori* infection in reducing the occurrence of RE.

### Mediation effect analysis of metabolic syndrome on *H. pylori* infection affecting reflux esophagitis


The  $\chi^2$  test was used to analyze metabolic syndrome and *H. pylori* infection; the incidence of metabolic syndrome was significantly higher in the *H. pylori*-infected group (1767/2856, 61.87%) than in the *H. pylori*-non-infected group (3017/5098, 59.18%; *P* = 0.019). The exposure variable was *H. pylori* infection, the outcome variable was RE, and metabolic syndrome was used as the mediating variable for the mediation effect analysis. The results showed that the total effect of *H. pylori* infection on RE was -0.121571, the direct effect of *H. pylori* infection on RE was -0.122715, the mediation effect of *H. pylori* infection on RE through metabolic syndrome was 0.001144, and the mediation effect accounted for -0.009413 in the total effect; the effects showed statistically significant differences (all *P*-values < 0.05) (Table 3). Metabolic syndrome had a partially negative mediating effect on *H. pylori* infection in reducing the occurrence of RE.

**Table 2** Mediation effect analysis: Immunoglobulin G-mediated food intolerance

Indicators	Effect value	95%CI	P value
Total effect	-0.122064	-0.138193, -0.104456	< 0.0001
Average direct effect	-0.119349	-0.135905, -0.102256	< 0.0001
Average mediation effect	-0.002715	-0.004145, -0.000316	0.0200
Average mediation effect percentage	0.022242	0.002679, 0.034859	0.0200

**Table 3** Mediation effect analysis: Metabolic syndrome

Indicators	Effect value	95%CI	P value
Total effect	-0.121571	-0.138064, -0.104781	< 0.0001
Average direct effect	-0.122715	-0.139268, -0.105907	< 0.0001
Average mediation effect	0.001144	0.000182, 0.002307	0.0220
Average mediation effect percentage	-0.009413	-0.018807, -0.001479	0.0220



**Figure 1** Multivariate analysis of influencing factors in reflux esophagitis. A: Model I was adjusted for age and sex; B: Model II was adjusted for age, sex, white blood cell count, hemoglobin, C-reactive protein, homocysteine, brain natriuretic peptide precursor, total protein, creatinine, 25-hydroxyvitamin D3, smoking history, and drinking history. Ig: Immunoglobulin.

## DISCUSSION

RE, also known as erosive esophagitis, is a type of GERD with a complex etiology and an increasing prevalence. Research on its pathogenesis has progressed in recent years, ranging from the invasion of reflux and the destruction of the anti-reflux barrier to immunity, inflammation and biomarkers on a systemic scale[14]. RE demonstrates a high rate of relapse after treatment and is associated with esophageal strictures, bleeding, carcinogenesis, and other complications, which affect the quality of life and long-term prognosis of patients. Therefore, it is critical to explore the risk factors for RE and implement early clinical interventions. The population prevalence of FI is 20% [4], resulting from reactions to food components, non-celiac gluten sensitivity, or defects in enzymes and transport[15]. Furthermore, food may induce inflammatory responses, which are crucial in the development of RE. Metabolic syndrome and its associated components are also risk factors for RE[6], and *H. pylori* infection plays an essential role in RE[8,10]. Therefore, the occurrence of RE may be associated with food reactions, *H. pylori* infection, and metabolic syndromes. This study focused on three relatively common clinical diseases, evaluated risk factors associated with the occurrence of RE, and explored the pathogenic effects of IgG-mediated FI, *H. pylori* infection, and metabolic syndrome on RE to provide a clinical basis for the etiology of the disease; this is crucial knowledge to prevent the occurrence of reflux and improve patients' quality of life.

Our study is the first to investigate the effects of IgG-mediated FI on RE in a large population and confirm that IgG-mediated FI contributes to the development of RE. Studies have suggested that diet may activate the immune system and alter the levels of inflammatory markers in the blood; increased pro-inflammatory cytokines and decreased anti-inflam-

matory cytokines have been linked to diet-associated immune system activation[16]. Furthermore, the promotion and release of inflammatory cytokines and cells during inflammatory reactions involve continuous interdependent cellular communication, which is crucial in the pathogenesis of GERD[1,17]. When FI occurs, a decrease in anti-inflammatory cytokines and the release of inflammatory cells and factors cause reflux; however, further studies are necessary to better understand this phenomenon. Most patients with FI are asymptomatic, which results in such patients receiving less attention[18]. In this study, the prevalence of IgG-mediated FI, which is crucial in the development of RE, was 61.77%; therefore, it is imperative to critically evaluate IgG-mediated FI. Screening for IgG-mediated FI in patients diagnosed with RE or in high-risk groups and avoiding related foods that induce FI in daily life may be crucial in reducing the occurrence of reflux.

This study suggests that metabolic syndrome is a risk factor for RE, consistent with other studies[6,7]. The pathological commonality between the diseases associated with metabolic syndrome is a chronic low-grade inflammation state, which activates various inflammatory signal cascades and leads to the activation of NF- $\kappa$ B, Jun amino-terminal kinase, and inflammatory processes; this results in the recruitment of immune cells, which further aggravates inflammation[19,20]. The mechanism by which metabolic syndrome promotes the development of RE may be associated with the mechanical effect of increased abdominal pressure caused by a large amount of adipose tissue. Furthermore, substances secreted by adipose tissue, such as TNF- $\alpha$ , IL-6, leptin, and insulin-like growth factor-1, significantly contribute to the occurrence, development, and carcinogenesis of GERD[6]. Therefore, controlling metabolic factors such as blood glucose, blood pressure, lipid levels, and body weight can significantly reduce the occurrence of RE.

In this study, *H. pylori* infection was considered a protective factor against RE. The possible mechanism has been analyzed: *H. pylori* infection causes gastric mucosal atrophy and acid production damage, and bacterial ammonia production neutralizes acidic substances and reduces acid reflux. Additionally, it leads to the activation of vagal receptors on the fundus and cardia, consequently increasing serum gastrin secretion, improving lower esophageal sphincter pressure, reducing reflux of gastric contents, and protecting the esophageal mucosa. The effect of *H. pylori* infection on reflux is controversial; some studies have suggested that *H. pylori* infection is a risk factor for RE, while others suggested that there is no relationship between them[8-10]. The possible reasons for the controversy between this study and other studies could be that other studies mostly assessed the impact of *H. pylori* eradication on RE through quality of life and reflux symptoms, and the drugs used to eradicate *H. pylori* significantly reduced the symptoms of reflux, which affected accuracy and confidence in the results. Therefore, screening for *H. pylori* infection is not routinely required for the clinical treatment of RE, and the treatment options for *H. pylori* infection are not indicated as anti-reflux therapy; this is consistent with the recommendations of the 2013 guidelines of the American College of Gastroenterology[21].

This study confirmed the effect of IgG-mediated FI and metabolic syndrome in reducing the occurrence of RE caused by *H. pylori* infection. A study conducted in southwest China revealed that *H. pylori* infection was negatively associated with food-specific IgG in eggs, milk, and wheat; this is consistent with the results of this study[22]. *H. pylori* infection stimulates the production of Foxp3+ regulatory T cells, which have strong immunosuppressive properties, control the degree of self and non-autoantigen reactions, and produce immune tolerance, consequently protecting against *H. pylori* infection. Immune tolerance suppresses the immune response caused by FI, which reduces the occurrence of RE. In people with FI, increased intestinal permeability allows food substances to enter the circulation; concurrently, the immune system recognizes certain food molecules as harmful substances and initiates an immune response to these substances, resulting in food-specific IgG[23], which further activates the immune effect and enhances the protective effect of *H. pylori* infection against the occurrence of RE. Therefore, IgG-mediated FI reduces the incidence of RE in patients with *H. pylori* infection. In addition, the results showed that *H. pylori* infection increased the incidence of metabolic syndrome. *H. pylori* infection can upregulate the expression of various inflammatory factors (including C-reactive protein, tumor necrosis factor, and various interleukins), promote insulin resistance, and initiate metabolic syndromes[24]. Metabolic syndrome results in chronic over-nutrition and excess energy, exceeding the metabolic capacity of tissues, which leads to metabolic stress and weakens the protective effect of *H. pylori* infection against reflux. Therefore, metabolic syndrome increases the incidence of RE in patients with *H. pylori* infection.

Lifestyle modification, dietary control, and pharmacotherapy are the primary treatment options for RE; however, the complex pathogenesis of RE and the critical role of the immuno-inflammatory cascade in its development may complicate the management of symptoms and increase susceptibility to relapse after treatment. This study evaluated the risk factors for RE and explored the effects of IgG-mediated FI, *H. pylori* infection, and metabolic syndrome on RE. Patients with IgG-mediated FI and metabolic syndrome were at a higher risk of RE; however, patients with *H. pylori* infection had a lower risk of RE. IgG-mediated FI reduced the risk of RE in patients with *H. pylori* infection; however, metabolic syndrome increased the risk of RE in patients with *H. pylori* infection. Therefore, in the management of RE, preventing the induction of IgG-mediated FI and optimal diagnosis and treatment of metabolic syndrome may reduce the occurrence of RE; this represents a strategy to achieve prevention and early treatment of RE in the future.

This was a single-center retrospective clinical study, and the test results showed certain deviations. Therefore, prospective and multicenter studies should be conducted to evaluate the factors influencing RE. The mechanisms underlying the effects of IgG-mediated FI, *H. pylori* infection, and metabolic syndrome in RE should be evaluated regarding the molecular perspective and the associated pathways.

## CONCLUSION

Patients with IgG-mediated FI and metabolic syndrome are at a higher risk of RE; however, patients with *H. pylori* infection have a lower risk of RE. IgG-mediated FI reduces the risk of RE in patients with *H. pylori* infection; however,

metabolic syndrome increases the risk of RE in patients with *H. pylori* infection.

## ARTICLE HIGHLIGHTS

### Research background

Reflux esophagitis has an increasing prevalence and complex and diverse symptoms. Identifying its risk factors is crucial to understanding the etiology, prevention, and management of the disease.

### Research motivation

The occurrence of reflux esophagitis may be associated with food reactions, *Helicobacter pylori* (*H. pylori*) infection, and metabolic syndromes.

### Research objectives

To investigate the risk factors for reflux esophagitis and analyze the effects of IgG-mediated food intolerance, *H. pylori* infection, and metabolic syndrome on reflux esophagitis.

### Research methods

This retrospective study analyzed endoscopic images of outpatients attending the Second Medical Center of PLA General Hospital between 2017 and 2021, classified them into non-RE and RE groups, and further explored the differences in IgG-mediated food intolerance, *H. pylori* infection, and metabolic syndrome of the different groups.

### Research results

In 7954 outpatients, the prevalence of reflux esophagitis was 20.84%.

### Research conclusions

Patients with IgG-mediated food intolerance and metabolic syndrome are at higher risk of developing reflux esophagitis, while those with *H. pylori* infection are at lower risk. IgG-mediated FI reduces the risk of RE in patients with *H. pylori* infection, while metabolic syndrome increases the risk of RE in these patients.

### Research perspectives

In the management of RE, preventing the induction of IgG-mediated FI and optimal diagnosis and treatment of metabolic syndrome may reduce the occurrence of RE.

## FOOTNOTES

**Co-first authors:** Li-Hui Wang and Bin-Bin Su.

**Co-corresponding authors:** Qian-Qian Chen and Hui Shi.

**Author contributions:** Su BB, Lv KM, Li Y, Shi H, and Chen QQ are gastroenterologists; Wang SS is a statistician; Wang LH and Sun GC are master degree candidates; Shi H and Chen QQ performed the disease diagnosis; Wang LH, Su BB, Shi H, and Chen QQ designed the research study; Su BB and Wang SS performed the primary literature and data extraction; Wang LH, Su BB, and Wang SS analyzed the data and wrote the manuscript; Sun GC, Lv KM, Li Y, Shi H, and Chen QQ revised the manuscript for important intellectual content; and all authors read and approved the final version.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the PLA General Hospital (Ethics audits No. S2022-414-01).

**Informed consent statement:** Patients were not required to provide informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to test by written consent.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Li-Hui Wang 0009-0007-8726-9166; Hui Shi 0009-0008-9300-5308; Qian-Qian Chen 0009-0006-9078-5711.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Yu HG

## REFERENCES

- 1 **Huo X**, Agoston AT, Dunbar KB, Cipher DJ, Zhang X, Yu C, Cheng E, Zhang Q, Pham TH, Tambar UK, Bruick RK, Wang DH, Odze RD, Spechler SJ, Souza RF. Hypoxia-inducible factor-2 $\alpha$  plays a role in mediating oesophagitis in GORD. *Gut* 2017; **66**: 1542-1554 [PMID: 27694141 DOI: 10.1136/gutjnl-2016-312595]
- 2 **Fass R**, Boeckstaens GE, El-Serag H, Rosen R, Sifrim D, Vaezi MF. Gastro-oesophageal reflux disease. *Nat Rev Dis Primers* 2021; **7**: 55 [PMID: 34326345 DOI: 10.1038/s41572-021-00287-w]
- 3 **Maret-Ouda J**, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. *JAMA* 2020; **324**: 2536-2547 [PMID: 33351048 DOI: 10.1001/jama.2020.21360]
- 4 **Tuck CJ**, Biesiekierski JR, Schmid-Grendelmeier P, Pohl D. Food Intolerances. *Nutrients* 2019; **11** [PMID: 31336652 DOI: 10.3390/nu11071684]
- 5 **Giugliano D**, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. *J Am Coll Cardiol* 2006; **48**: 677-685 [PMID: 16904534 DOI: 10.1016/j.jacc.2006.03.052]
- 6 **Fu S**, Xu M, Zhou H, Wang Y, Tan Y, Liu D. Metabolic syndrome is associated with higher rate of gastroesophageal reflux disease: a meta-analysis. *Neurogastroenterol Motil* 2022; **34**: e14234 [PMID: 34378835 DOI: 10.1111/nmo.14234]
- 7 **Niigaki M**, Adachi K, Hirakawa K, Furuta K, Kinoshita Y. Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan. *J Gastroenterol* 2013; **48**: 463-472 [PMID: 22976934 DOI: 10.1007/s00535-012-0671-3]
- 8 **Zhao T**, Liu F, Li Y. Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms. *Front Cell Infect Microbiol* 2023; **13**: 1082620 [PMID: 36968099 DOI: 10.3389/fcimb.2023.1082620]
- 9 **Hirata K**, Suzuki H, Matsuzaki J, Masaoka T, Saito Y, Nishizawa T, Iwasaki E, Fukuhara S, Okada S, Hibi T. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. *J Clin Biochem Nutr* 2013; **52**: 172-178 [PMID: 23524980 DOI: 10.3164/jcfn.12-107]
- 10 **Yucel O**. Interactions between Helicobacter pylori and gastroesophageal reflux disease. *Esophagus* 2019; **16**: 52-62 [PMID: 30151653 DOI: 10.1007/s10388-018-0637-5]
- 11 **Coucke F**. Food intolerance in patients with manifest autoimmunity. Observational study. *Autoimmun Rev* 2018; **17**: 1078-1080 [PMID: 30213697 DOI: 10.1016/j.autrev.2018.05.011]
- 12 **Alberti KG**, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009; **120**: 1640-1645 [PMID: 19805654 DOI: 10.1161/CIRCULATIONAHA.109.192644]
- 13 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]
- 14 **Hu JY**, Lv M, Zhang KL, Qiao XY, Wang YX, Wang FY. Evaluating the causal relationship between human blood metabolites and gastroesophageal reflux disease. *World J Gastrointest Oncol* 2023; **15**: 2169-2184 [PMID: 38173433 DOI: 10.4251/wjgo.v15.i12.2169]
- 15 **Lomer MC**. Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance. *Aliment Pharmacol Ther* 2015; **41**: 262-275 [PMID: 25471897 DOI: 10.1111/apt.13041]
- 16 **Ohtsuka Y**. Food intolerance and mucosal inflammation. *Pediatr Int* 2015; **57**: 22-29 [PMID: 25442377 DOI: 10.1111/ped.12546]
- 17 **Hait EJ**, McDonald DR. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders. *Clin Rev Allergy Immunol* 2019; **57**: 213-225 [PMID: 30206783 DOI: 10.1007/s12016-018-8701-4]
- 18 **Turnbull JL**, Adams HN, Gorard DA. Review article: the diagnosis and management of food allergy and food intolerances. *Aliment Pharmacol Ther* 2015; **41**: 3-25 [PMID: 25316115 DOI: 10.1111/apt.12984]
- 19 **Catrysse L**, van Loo G. Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF- $\kappa$ B. *Trends Cell Biol* 2017; **27**: 417-429 [PMID: 28237661 DOI: 10.1016/j.tcb.2017.01.006]
- 20 **Grandl G**, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. *Semin Immunopathol* 2018; **40**: 215-224 [PMID: 29209827 DOI: 10.1007/s00281-017-0666-5]
- 21 **Katz PO**, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol* 2013; **108**: 308-28; quiz 329 [PMID: 23419381 DOI: 10.1038/ajg.2012.444]
- 22 **Liu Y**, Shuai P, Liu YP, Li DY. Association between Helicobacter pylori infection and food-specific immunoglobulin G in Southwest China. *World J Clin Cases* 2021; **9**: 9815-9824 [PMID: 34877320 DOI: 10.12998/wjcc.v9.i32.9815]
- 23 **Shakoor Z**, AlFaifi A, AlAmro B, AlTawil LN, AlOhalay RY. Prevalence of IgG-mediated food intolerance among patients with allergic symptoms. *Ann Saudi Med* 2016; **36**: 386-390 [PMID: 27920409 DOI: 10.5144/0256-4947.2016.386]
- 24 **Cheng DD**, He C, Ai HH, Huang Y, Lu NH. The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease. *Front Microbiol* 2017; **8**: 743 [PMID: 28539915 DOI: 10.3389/fmicb.2017.00743]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

